

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, Representative Director, President and CEO  
(Code no.: 4568, First Section, Tokyo Stock Exchange)  
Please address inquiries to Noriaki Ishida, Corporate Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com/>

### **Daiichi Sankyo Selects Research Partners for TaNeDS Collaborative Drug Discovery Project**

**Tokyo, Japan (November 11, 2014)**— Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners for its 2014 TaNeDS (**T**ake a **N**ew challenge for **D**rug di**S**covery) collaborative drug discovery project.

TaNeDS, which began in 2011 as part of Daiichi Sankyo's open innovation program, selects researchers from universities and public research centers in Japan, and Daiichi Sankyo will soon begin signing agreements with this year's selected parties to initiate collaborative research.

1. Total entries: 234

2. Selected parties: 24

3. Selections by entry type

	Entries	Passed second selection	Final selections
A. Daiichi Sankyo's Desired Research Themes (Entries with multiple types are counted once for each types)	228	36	23
a. Drug discovery target verification	114	18	9
b. Drug discovery target investigation	113	9	6
c. Drug discovery technology development/verification	68	8	7
d. Pharmaceutical technology	3	1	1
B. Daiichi Sankyo RD Novare's Desired Research Themes*	6	1	1
Total	234	37	24

\* Daiichi Sankyo RD Novare Co., Ltd. (hereafter, RD Novare), Daiichi Sankyo's wholly owned subsidiary, joined TaNeDS to promote the development of novel technology platforms for drug discovery from 2013.

4. Selections by research theme

	Entries	Passed second selection	Final selection
A. Daiichi Sankyo's Desired Research Themes	95	11	5

• Oncology			
• Cardiovascular metabolics	71	5	3
• Other disorders	62	10	6
• Biologics	41	2	2
• Pathology/vital imaging	6	1	1
• Measuring technology	14	1	1
• Drug safety	10	2	2
• ADME (Drug Absorption, Distribution, Metabolism, Excretion)	15	1	1
• Pathology/in silico models related to drug effect estimates	3	1	0
• Biomedicine safety technology	2	1	1
• Screening-related technology	1	0	0
• New synthetic technology	0	0	0
• Vaccines	17	1	1
B. RD Novare's Desired Research Themes	6	1	1
• Drug discovery and development technology platform research			
Total (Entries with multiple themes are counted once for each theme)	337	37	24

For reference: 2014 TaNeDS project overview (from March 25, 2014, press release)

# 1. Project overview

## (1) How to apply

Two project types have been set up for 2014 based on the results of applications and projects adopted in 2013, and with the participation of RD Novare this year in mind.

Project type		Duration	Scope of funding (total)
A. Daiichi Sankyo's Desired Research Themes	a. Drug discovery target verification	Completion of contract to March 31, 2016	Up to 10 million yen
	b. Drug discovery target investigation	Completion of contract within 2 years	Up to 10 million yen
	c. Drug discovery technology development/verification	Completion of contract to March 31, 2016	Up to 10 million yen
	d. Pharmaceutical technology	Completion of contract for 1 or 2 years	Up to 20 million yen (10 million yen/year)
B. RD Novare's Desired Research Themes	Drug discovery and development technology platforms	Completion of contract to March 31, 2016	Up to 5 million yen

\*Project duration subject to change based on research.

A. Desired research themes by Daiichi Sankyo:

- a) Drug discovery target verification - Research themes that will lead to the verification of new drug targets, regarding elements found in exploratory/discovery research, through methods including analysis of body functions and of pathology samples, will be accepted.
- b) Drug discovery target investigation – Research themes that will lead to the discovery/identification of new drug targets, based on unique research tools or ideas, will be accepted.
- c) Drug discovery technology development/verification – Research technology themes that help to revitalize or improve effectiveness of drug discovery research will be accepted.
- d) Pharmaceutical technology – Research themes that will solve issues related to the pharmaceutical manufacturing process will be accepted.

Daiichi Sankyo will determine if feasibility studies with Daiichi Sankyo researchers (preliminary collaborative research) or collaborative research should be conducted based on proposed themes. Accepted themes will be selected for continuation based on results after the research period comes to close.

B. Desired research themes by RD Novare:

Research themes that will lead to the development of the novel technology platforms related to drug discovery and development will be accepted. Scientists at RD Novare work together on lead technologies being researched academically by applicants to establish leading edge technology platforms and biological evaluation methods.

(2) Desired research themes

A. Desired research themes by Daiichi Sankyo

- a) Drug discovery target verification
  - i. Oncology
  - ii. Cardiovascular metabolics (metabolic disease, heart disease and vascular disease)
  - iii. Other disorders
  - iv. Vaccines
- b) Drug discovery target investigation
  - v. Oncology
  - vi. Cardiovascular metabolics (metabolic disease, heart disease and vascular disease)
  - vii. Other disorders
  - viii. Vaccines
- c) Drug discovery technology development/verification
  - ix. Biologics
  - x. Pathology/vital imaging
  - xi. Measuring technology
  - xii. Drug safety
  - xiii. ADME (Drug Absorption, Distribution, Metabolism, Excretion)
  - xiv. Pathology/*in silico* models related to drug effect estimates
  - xv. Vaccines
- d) Pharmaceutical technology
  - xvi. Biomedicine safety technology
  - xvii. Screening-related technology
  - xviii. New synthetic technology

B. Desired research themes by RD Novare

Drug discovery and development technology platform research

(3) Who is eligible?

Researchers from universities and public research institutions who can conduct research in Japan

(4) Schedule

Application period:	May 19 to June 16, 2014
First selection period:	June 17 to July 31, 2014
Second selection period:	August 1 to September 30, 2014
Contract negotiation:	From October 1, 2014
Start of research:	Upon completion of contract

\*For more information about the TaNeDS program, please visit the Daiichi Sankyo corporate website (in Japanese) at: <http://www.daiichisankyo.co.jp/corporate/rd/taneds> (Japanese only)